Cantor Fitzgerald Estimates Humana FY2026 Earnings

Humana Inc. (NYSE:HUM) – Stock analysts at Cantor Fitzgerald issued their FY2026 EPS estimates for Humana in a research note issued on Monday, June 9th. Cantor Fitzgerald analyst S. James anticipates that the insurance provider will post earnings per share of $14.58 for the year. Cantor Fitzgerald currently has a “Neutral” rating and a $290.00 target price on the stock. The consensus estimate for Humana’s current full-year earnings is $16.47 per share.

Humana (NYSE:HUM) last announced its quarterly earnings results on Wednesday, April 30th. The insurance provider reported $11.58 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $10.07 by $1.51. The company had revenue of $32.11 billion for the quarter, compared to the consensus estimate of $32 billion. Humana had a net margin of 1.02% and a return on equity of 11.70%. Humana’s revenue for the quarter was up 8.4% compared to the same quarter last year. During the same period in the previous year, the firm posted $7.23 EPS.

A number of other research firms also recently commented on HUM. Robert W. Baird increased their target price on Humana from $270.00 to $300.00 and gave the company a “neutral” rating in a research report on Tuesday, April 15th. Wall Street Zen raised shares of Humana from a “hold” rating to a “buy” rating in a research note on Friday, May 9th. JPMorgan Chase & Co. decreased their target price on shares of Humana from $257.00 to $256.00 and set a “neutral” rating on the stock in a research report on Tuesday, February 18th. Guggenheim initiated coverage on shares of Humana in a report on Wednesday, April 9th. They issued a “buy” rating and a $326.00 price target for the company. Finally, Oppenheimer boosted their price objective on Humana from $300.00 to $310.00 and gave the stock an “outperform” rating in a research note on Thursday, May 1st. Sixteen investment analysts have rated the stock with a hold rating and eight have assigned a buy rating to the stock. According to MarketBeat, the company presently has an average rating of “Hold” and a consensus target price of $284.48.

Humana Price Performance

Shares of Humana stock opened at $233.04 on Tuesday. The firm has a market cap of $28.13 billion, a PE ratio of 23.42, a PEG ratio of 2.05 and a beta of 0.43. The stock has a 50 day moving average of $252.85 and a 200 day moving average of $264.23. The company has a current ratio of 1.76, a quick ratio of 1.76 and a debt-to-equity ratio of 0.68. Humana has a 12 month low of $212.45 and a 12 month high of $406.46.

Institutional Investors Weigh In On Humana

Institutional investors and hedge funds have recently bought and sold shares of the company. FPC Investment Advisory Inc. purchased a new position in shares of Humana during the fourth quarter valued at $27,000. Centricity Wealth Management LLC bought a new stake in shares of Humana in the 4th quarter valued at about $30,000. Cary Street Partners Investment Advisory LLC lifted its position in shares of Humana by 63.9% in the 1st quarter. Cary Street Partners Investment Advisory LLC now owns 118 shares of the insurance provider’s stock worth $31,000 after purchasing an additional 46 shares during the period. LFA Lugano Financial Advisors SA lifted its position in shares of Humana by 56.3% in the 4th quarter. LFA Lugano Financial Advisors SA now owns 125 shares of the insurance provider’s stock worth $32,000 after purchasing an additional 45 shares during the period. Finally, Riverview Trust Co bought a new position in shares of Humana during the first quarter valued at approximately $34,000. 92.38% of the stock is owned by institutional investors.

Humana Announces Dividend

The company also recently disclosed a quarterly dividend, which will be paid on Friday, July 25th. Shareholders of record on Friday, June 27th will be issued a dividend of $0.885 per share. The ex-dividend date of this dividend is Friday, June 27th. This represents a $3.54 annualized dividend and a yield of 1.52%. Humana’s payout ratio is currently 25.04%.

About Humana

Humana Inc, together with its subsidiaries, provides medical and specialty insurance products in the United States. It operates through two segments, Insurance and CenterWell. The company offers medical and supplemental benefit plans to individuals. It has a contract with Centers for Medicare and Medicaid Services to administer the Limited Income Newly Eligible Transition prescription drug plan program; and contracts with various states to provide Medicaid, dual eligible, and long-term support services benefits.